% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • sy3dney sy3dney Jan 29, 2013 2:47 PM Flag

    Chugia Pharmaceutical Files New Drug Application for T-DM1 in Japan

    January 29, 2013 (Tokyo) – Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that it has filed a new drug application to the Ministry of Health, Labour and Welfare (MHLW), for antibody-drug conjugate "trastuzumab emtansine (T-DM1)" for the treatment of "HER2-positive metastatic or recurrent breast cancer."

    Chugai filed the application with the MHLW based on the results from an overseas phase III clinical trial (the EMILIA trial) and a domestic phase II clinical trial.

    The EMILIA trial is an international phase III study comparing T-DM1 alone to lapatinib in combination with capecitabine in people with HER2-positive metastatic or unresectable locally advanced breast cancer who had previously been treated with trastuzumab and a taxane chemotherapy. Japanese patients were not included in the EMILIA trial.

    The EMILIA trial had progression free survival (PFS) as one of its primary endpoints, and patients who received T-DM1 experienced a 35 percent reduction in the risk of their disease worsening or death compared to those who received lapatinib plus capecitabine. The median PFS improved by 3.2 months from 6.4 months of lapatinib and capecitabine to 9.6 months of T-DM1 (hazard ratio=0.65; p

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.98-0.15(-4.79%)Jun 27 4:00 PMEDT